DocMorris: Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life
(Berlin, Germany): – In January, Zur Rose Group announced its partnership with Novo Nordisk to raise awareness of obesity and to improve access to the right information, diagnosis and care for people living with this condition. Obesity (BMI >30) is a disease that affects a quarter of the adult German population (23% of men and 24% of women)1, a segment of the population at increased risk for many other serious diseases and health conditions like diabetes, cardiovascular diseases and musculoskeletal disorders2. To reduce the risk of health complications and improve their quality of life, people living with obesity share a need to reduce their weight, address the mental health implications of the disease and cope with the social stigmas associated to their condition. Today, the collaboration starts with the new web-based health experience and individual-relevant Hub: Adipositas Care supported by an insights-based obesity awareness campaign for people living with obesity.
“Thanks to our collaboration with Novo Nordisk, today marks the beginning of a new era for people living with obesity” says Betül Susamis Unaran, Chief Strategy and Digital Officer of the Zur Rose Group. “The new obesity health journey empowers people living with the condition by bringing forward a new way for them to access best possible care solutions, enabling them to get informed about their disease and linking them to online and offline specialized doctors and advisors in obesity care. The launch of this new health experience is a critical step in bringing Zur Rose Group’s ecosystem vision to life: in creating a world where everyone can manage their health in one click.”
Creating a new, individual relevant health experience
DocMorris Adipositas Care puts people with obesity in the center of the experience by addressing their key concerns. The hub release today is the first product version that will continue to be developed and improved over the next months. Features of the launch release include:
- Education that addresses weight loss, mental health, obesity stigmas and empowers people with obesity to take better healthcare decisions: The hub supports people with obesity to better understand their condition, the reasons behind their difficulty in losing and maintaining weight as well as the potential causes of obesity.
- Support on how to get started and ways to address top concerns: Guided by their most common concerns, the hub supports people living with obesity to access relevant content, treatment options adopted by peers and links to medical help and counseling.
- Discovery of best possible treatment options for this chronic condition: Many people living with obesity have tried various approaches to manage their weight and associated challenges. The hub enables them to discover possible treatment options such as medication, digital therapeutics and surgery provided by specialized healthcare professionals in obesity care.
- Link to specialized doctors and advisors in obesity: The hub enables access to specialized doctors online via a dedicated section at TeleClinic, Germany`s leading provider of telemedicine, and offline doctors and advisors via adipositas-spezialisten.de a tool to locate healthcare practitioners with obesity expertise in Germany.
A key step forward for the DocMorris European healthcare ecosystem
The DocMorris Adipositas Care hub anchors in the strategic expansion of the DocMorris brand – from pharmaceuticals to a consumer-centric digital healthcare platform, as the umbrella brand for the Zur Rose Group's European healthcare ecosystem.The new DocMorris Adipositas Care hub reflects Zur Rose Group’s vision of creating a world where everyone can get convenient access to health – anytime, anywhere, just one click away.
Experience DocMorris Adipositas Care here: www.docmorriscare.com/adipositas
[1] RKI DEGS 1 Study 2012. Available from:
https://www.rki.de/DE/Content/Gesundheitsmonitoring/Themen/Uebergewicht_Adipositas/Uebergewicht_Adipositas_node.html
[2] World Health Organization 2020, Obesity and overweight, United Nations. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [January 2021]
Contacts
Media contact
Segment Germany of the Zur Rose Group:
Torben Bonnke, Director Communication & PR
Email: torben.bonnke@docmorris.de, phone +49 30 21222 36 12
eHealth ecosystem contact
Betül Susamis Unaran, Chief Strategy and Digital Officer
Email: betul.unaran@zurrose.com, phone +41 79 834 41 40
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Sony Music Entertainment: The Whole World is Dancing to "Chicken Banana" TikTok's New Obsession – And Already One of 2025's Biggest Viral Hits15.5.2025 12:00:00 CEST | Press release
Listen to the song here: https://www.youtube.com/watch?v=ig7EKb6BrQk
Prof Dr Klemens Joos back as CEO of the EUTOP Group14.5.2025 13:27:53 CEST | Press release
Brussels - Prof Dr Klemens Joos (56) has been back at the helm of the EUTOP Group as CEO since 13 May 2025. The background to this is an ambitious growth strategy up to 2035 for the EUTOP Group, which he founded in 1990 while studying business administration at the Ludwig Maximilian University (LMU) in Munich. Just one year after its foundation, the company had a representative office in Brussels. Today, the EUTOP Group has subsidiaries or representative offices in the capitals of all major European Union member states in addition to Brussels. Prof Dr Klemens Joos is also an honorary professor of ‘Business Administration - Political Stakeholder Management’ at the Technical University of Munich (TUM). Enquiries & Contact: Press department EUTOP Group +49 89 323700-0 eutop@eutop.eu
New record achieved: NTT DATA Business Solutions exceeds the previous year’s top figures in terms of both revenue and results12.5.2025 11:12:03 CEST | Press release
2024/2025 saw a double-digit revenue growth of 14.7 percent to 1.85 billion euros EBIT in three digits for the first time at 109.9 million euros (+35.9%) Close to a 50 percent increase in cloud subscriptions Proportion of international business tops 60 percent mark Optimistic outlook despite global uncertainties
Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase9.5.2025 12:00:00 CEST | Press release
(Vienna, Austria) Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease. Biomay is the FDA-approved manufacturer of recombinant Cas9 as the essential component of CASGEVY®, the very first CRISPR genome editing product on the market. Biomay’s Cas9 (internal code “BMC9”) is based on the classical wild-type Cas9 nuclease from Streptococcus pyogenes. The Cas9 manufacturing process has been de novo developed, GMP-implemented and PPQ-validated by Biomay. GMP and RUO manufacturing is performed by fermentation with E. coli and by purification with chromatographic methods. By quality control with a comprehensive set of validated analytical assays, the consistent
mAInthink GmbH: Technological Breakthrough: Hallucination-Free Superintelligence Achieves 99.99% Strategic Accuracy – Germany Gains Permanent Strategic Superiority9.5.2025 10:57:00 CEST | Press release
Worms, May 9, 2025 – The mAInthink GmbH has achieved a technological breakthrough that redefines the future of strategic decision-making: With the development of StratePlan, a hallucination-free superintelligence delivering verified 99.99% strategic accuracy, Germany secures permanent technological, economic, and geopolitical superiority – operationally deployable and scientifically validated.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom